Neuroprotective effects of erythropoietin against oxidant injury following brain irradiation: an experimental study

Uğurluer, Gamze; Çebi, Ayşegül; Mert, Handan; Mert, Nihat; Serin, M.; Erkal, Haldun Şükrü

doi:10.5114/aoms.2016.58622

Cited by 9 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has previously been demonstrated that infusion of β-amyloid in rats resulted in significant decrease of the antioxidant capacity [32,33]. Oxidative stress and related degeneration of cholinergic neurons is one of the most common sharing pathways involved in neurodegenerative disorders such as AD [34][35][36]. The brain is more susceptible to reactive oxygen species (ROS)-mediated injury because its cellular membranes are preferentially enriched in oxyradical-sensitive polyunsaturated fatty acids that are the substrates of lipid peroxidation.…”

Section: Discussionmentioning

confidence: 99%

Effect of β-asarone in normal and β-amyloid-induced Alzheimeric rats

Saki¹,

Eidi²,

Mortazavi³

et al. 2020

aoms

View full text Add to dashboard Cite

Introduction: β-Asarone is a major component of Acorus tatarinowii Schott. It has pharmacological effects that include antihyperlipidemic, anti-inflammatory, and antioxidant activity. In the present study, the effect of β-asarone on neurodegeneration induced by intrahippocampal administration of β-amyloid was investigated in adult male Wistar rats. Material and methods: The rats were randomly divided into 9 groups: normal control, sham-operated control, β-asarone (12.5, 25, and 50 mg/kg intragastrically, daily) alone, Alzheimeric control rats (β-amyloid, intrahippocampal), β-asarone (12.5, 25, and 50 mg/kg intragastrically, daily) together with β-amyloid, and treatment was performed accordingly. Animals were injected with β-amyloid bilaterally. Animals received β-asarone daily using an intragastric tube for 50 days, starting from 30 days before administration of the β-amyloid. The rats were sacrificed and parameters of oxidative stress, superoxide dismutase (SOD) and glutathione peroxidase (GPX) activity were measured in hippocampus homogenate. Histopathological changes were examined by Bielschowsky staining. Results: Our results showed that administration of β-asarone (25 and 50 mg/ kg) significantly increased the levels of antioxidant enzymes, including SOD (1.09 ±0.02, 1.21 ±0.02, p < 0.001, respectively) and GPX (58.94 ±0.78, 68.92 ±3.64, p < 0.001, respectively) in comparison with Alzheimeric control rats (SOD and GPX level for Alzheimeric control group: 0.44 ±0.01, 35.09 ±1.15, respectively). Histopathological examination showed that β-asarone decreased cell loss in the cerebral cortex and hippocampus in Alzheimeric rats. Conclusions: These results indicate that β-asarone is effective in providing protection against oxidative stress and neuronal damage induced by β-amyloid.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of β-asarone in normal and β-amyloid-induced Alzheimeric rats

Saki¹,

Eidi²,

Mortazavi³

et al. 2020

aoms

View full text Add to dashboard Cite

show abstract

“…Ugurluer evaluated the effect of Epo against oxidant injury following brain radiotherapy in experimental model. He showed a pos-itive neuroprotective effect of Epo connected with decreasing free radical production and increasing expression of antioxidant enzymes [42].…”

Section: The Neuroprotective Effects Of Erythropoietinmentioning

confidence: 99%

The influence of erythropoietin on apoptosis and fibrosis in the early phase of chronic pancreatitis in rats

et al. 2021

View full text Add to dashboard Cite

Introduction: Chronic pancreatitis (CP) is a continuing, inflammatory process of the pancreas, characterised by irreversible morphological changes. The identification of pancreatic stellate cells resulted in the development of research on the pathogenesis of CP. Erythropoietin (Epo) regulates the interaction between apoptosis and inflammation of the brain, kidney, and heart muscle. Erythropoietin receptors were also found in the pancreas, in particular on the islet cells. Our objective was to evaluate the influence of Epo on fibrosis and apoptosis in experimental CP. Material and methods: The experiments were performed on 48 male Wistar rats (250-350 g). The animals were divided into six equal groups (I-control, II-chronic cerulein-induced pancreatitis, III-1 ml of Epo sc, IV-0.5 ml of Epo sc, V-CP treated with 1 ml Epo, VI-CP treated with 0.5 ml Epo). The blood for gelatinases and pancreata for the morphological examinations and immunohistochemistry were collected. Results: A slight reduction of interstitial oedema and less severe fibrosis were noticed in the groups treated with Epo. Reduced expression of caspase-3 and α-actin, and a lack of Bcl-2 expression were observed in areas with inflammation. There was no expression of caspase-9 observed in all groups. There were no statistically significant differences between the groups in the activity of gelatinases. Conclusions: Erythropoietin seems to have the effect of reducing fibrosis and apoptosis in an experimental model of CP.

show abstract

“…It is believed that EPO protects neurons through a combination of these mechanisms. [7,8] EPO modulates neuroinfl ammation through neurotrophic actions on astrocytes, microglia and neurons. [9] It can pass through the blood-brain barrier and acts on the central nervous system through inhibition of apoptosis in microvascular endothelial cells and activation of astrocytes.…”

Section: Introductionmentioning

confidence: 99%

Short-term Tolerance of Nasally-administered NeuroEPO in Patients with Parkinson Disease

et al. 2021

View full text Add to dashboard Cite

The safety and tolerance of NeuroEPO have been proven in healthy people [13] (Cuban Public Registry of Clinical Trials RPCEC00000157) but there is no evidence yet of PD patients' tolerance of the drug.This study evaluates short-term tolerance of intranasally administered NeuroEPO in patients with PD stages 1 and 2 on the Hoehn and Yahr Scale.[14] It examines the onset of adverse events and their potential effect on blood pressure and hematological variables. METHODSA monocentric randomized placebo-controlled double-blind clinical trial (registered at www.clinicaltrials.gov number NCT04110678) was conducted to evaluate tolerance and safety of NeuroEPO in PD patients.

show abstract

Neuroprotective effects of erythropoietin against oxidant injury following brain irradiation: an experimental study

Cited by 9 publications

References 30 publications

Effect of β-asarone in normal and β-amyloid-induced Alzheimeric rats

Effect of β-asarone in normal and β-amyloid-induced Alzheimeric rats

The influence of erythropoietin on apoptosis and fibrosis in the early phase of chronic pancreatitis in rats

Short-term Tolerance of Nasally-administered NeuroEPO in Patients with Parkinson Disease

Contact Info

Product

Resources

About